What is the recommended treatment approach for May‑Thurner syndrome (MTS)?

Treatment of May-Thurner Syndrome

Combined iliac vein stenting with catheter-directed thrombolysis (CDT) or pharmacomechanical thrombectomy (PMT) plus therapeutic anticoagulation is the preferred treatment for May-Thurner syndrome presenting with acute deep vein thrombosis; anticoagulation alone leads to significantly higher recurrent VTE rates and fails to address the persistent anatomic compression. 1

Initial Management Upon Diagnosis

Immediate Anticoagulation

• Start therapeutic anticoagulation immediately upon diagnosis of May-Thurner-related DVT 1
• Direct oral anticoagulants (DOACs)—apixaban, rivaroxaban, edoxaban, or dabigatran—are strongly preferred over warfarin due to lower bleeding risk 2
• If warfarin is used, target INR 2.5 (range 2.0–3.0) 2
• Low molecular weight heparin (LMWH) is an acceptable alternative for patients unable to tolerate DOACs 2, 3

Diagnostic Confirmation

• Obtain duplex ultrasound as first-line imaging to confirm DVT 3
• Proceed to CT venography or MR venography to delineate thrombus extent and identify iliac vein compression 1, 3
• Young, otherwise healthy patients with acute left-sided DVT should raise immediate suspicion for May-Thurner syndrome 1

Definitive Endovascular Treatment Algorithm

For Acute DVT (< 14 Days from Symptom Onset)

Step 1: Thrombus Removal

• Perform catheter-directed thrombolysis (CDT) or pharmacomechanical thrombectomy (PMT) to remove thrombus burden before stenting 1
• PMT reduces required thrombolytic drug dose by 40–50% and shortens infusion time compared with CDT alone 1
• Do not delay intervention; early thrombus removal within 14 days yields optimal outcomes 1
• Percutaneous mechanical thrombectomy using devices like the Inari ClotTriever achieves 100% technical success and can be performed in outpatient settings 4

Step 2: Stent Placement

• After thrombus removal, perform balloon angioplasty followed by self-expanding iliac vein stent placement 1
• Angioplasty alone typically fails; stenting is required 1
• Confine stents to the iliac vein whenever feasible to optimize long-term patency 1
• If the lesion extends into the common femoral vein, caudal stent extension is reasonable, though patency is modestly lower (90% vs 84%) 1
• For isolated common femoral vein stenosis, attempt percutaneous transluminal angioplasty without stenting first 1

For Chronic or Non-Thrombotic Presentation

• Stent placement without prior thrombolysis achieves 83–98% anatomic success for chronically occluded iliac veins 1
• This strategy significantly improves quality-of-life scores and enables venous ulcer healing in approximately 56% of patients 1

For Phlegmasia Cerulea Dolens (Limb-Threatening Emergency)

• Anticoagulation alone is inadequate; urgent thrombus removal is required to prevent limb loss 1, 3
• CDT or PMT is first-line treatment (Class I recommendation) 1
• Surgical thrombectomy is reserved for contraindications to thrombolysis, endovascular failure, or imminent gangrene 1

Post-Stenting Anticoagulation Protocol

Initial 3-Month Phase

• Continue therapeutic anticoagulation with the same dosing and monitoring as for iliofemoral DVT patients without stents 1, 2
• DOACs remain strongly preferred over warfarin 2
• Minimum duration is 3 months 1, 2

Extended Anticoagulation (Beyond 3 Months)

Indefinite therapy is recommended for May-Thurner syndrome even after stenting, because the chronic anatomic compression persists as a risk factor. 2

• For unprovoked DVT or persistent risk factors (including May-Thurner syndrome), continue anticoagulation indefinitely 2
• Two acceptable approaches exist: standard-dose DOAC (same therapeutic dose) or reduced-dose DOAC (rivaroxaban 10 mg daily or apixaban 2.5 mg twice daily) based on bleeding risk 2

Exception for low-risk patients:

• In younger patients with patent stents, no prior VTE, and confirmed May-Thurner anatomy, stopping anticoagulation after 3–12 months is considered safe 1

Adjunctive Antiplatelet Therapy

• Add antiplatelet therapy to anticoagulation only in high-risk patients (poor inflow vein quality, suboptimal anatomic result) after individualized bleeding-risk assessment 1
• Dual therapy increases bleeding risk and should be reserved for selected cases 1

Compression Therapy

• Prescribe 30–40 mm Hg knee-high elastic compression stockings for at least 2 years to reduce post-thrombotic syndrome risk by approximately 50% 1, 3
• Initiate within 1 month of diagnosis and continue for minimum 1 year 3

Expected Clinical Outcomes

• At 3 years after stenting, 79% of patients maintain pain reduction and 66% maintain swelling reduction 1
• Primary stent patency with anticoagulation approaches 60–100% at one year 2
• Stent placement after thrombus removal significantly reduces early rethrombosis compared with thrombus removal alone 3

Critical Pitfalls to Avoid

Do not rely on anticoagulation alone when May-Thurner syndrome is identified—the persistent anatomic compression predisposes to recurrent VTE regardless of anticoagulation. 1, 2

• Anticoagulation does not address the mechanical compression; stenting is essential 2
• Recurrent VTE occurs more frequently with anticoagulation alone compared with thrombectomy followed by stenting 1

Other important considerations:

• Stent fracture is rare (~1% of cases) and can usually be managed by implanting a second stent 1, 5
• In pregnant patients with prior iliac vein stents, mechanical deformation may occur late in pregnancy but typically resolves spontaneously postpartum without clinical sequelae 1
• Among 62 pregnant women with left iliac vein stents receiving LMWH prophylaxis, no recurrent VTE occurred during pregnancy or postpartum 1

Special Populations

Cancer Patients

• Oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are preferred over LMWH 2
• Extended anticoagulation is recommended 2

Pregnancy and Postpartum

• LMWH is the anticoagulant of choice, as warfarin crosses the placenta and causes embryopathy between 6–12 weeks' gestation 3

Outpatient Management

• Patients with acute iliofemoral DVT and May-Thurner syndrome can be managed with ambulatory DOAC initiation and subsequent outpatient PMT, angioplasty, and stenting 4
• This approach avoids inpatient hospitalization expense while maintaining equivalent 12-month primary patency rates (73.5% inpatient vs 86.7% outpatient) 4